Targovax appoints Oystein Soug as CEO
Staff Writer | Oslo, Norway | November 3, 2016
November 3, 2016, Oslo, Norway - Targovax, an immuno-oncology company, announced that it has appointed Oystein Soug, currently the company's chief financial officer, to the role of chief executive officer.
Mr. Soug is the former CFO of Algeta, a Norwegian oncology biotech company which was sold to Bayer in 2014.
Prior to joining Algeta in 2008 Mr. Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division.
Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development.
Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997. ■
Prior to joining Algeta in 2008 Mr. Soug worked for six years at Orkla, lastly as CFO of Orkla’s Russian division.
Mr. Soug started his career as a banker with Credit Suisse and with the European Bank for Reconstruction and Development.
Mr. Soug received an MSc in Economics and Financial Markets from Universität St. Gallen in Switzerland in 1997. ■
